OpenAI's Charity Is Buying Dead Biotech Data to Speed Up Cures

OpenAI's charitable parent, the OpenAI Foundation, just launched a program called Public Data for Health. Its goal is simple to say and hard to do: feed AI systems much more information about biology so they can help discover and develop new medicines. Right now, the biggest problem isn't the AI — it's the lack of data to teach it with.

One grant of $500,000 funds a clever idea from policy analyst Ruxandra Teslo. When biotech companies go bankrupt, their detailed drug research — safety tests, manufacturing plans, regulatory filings — often gets locked away as trade secrets. Her plan is to buy those files at bankruptcy auctions and share them. A group she advises, 1Day Sooner, already holds three such datasets and thinks more can be bought for just tens of thousands of dollars each. The foundation also announced $40 million for cancer vaccine data at the University of North Carolina and support for contests that predict how drugs will affect people.

Why should you care? Bringing a new drug to market is slow, expensive, and often fails. If AI can learn from thousands of past successes and failures, it could spot promising treatments faster and cheaper — meaning new medicines reach patients sooner. The foundation says data is the single biggest bottleneck holding back AI in medicine.

The catch is twofold. First, the foundation is brand new at giving money away — it's still hiring staff and only started ramping up this year, though it hopes to hand out $1 billion by December. Second, this push comes as insiders warn that powerful AI could be misused to create bioweapons. Even OpenAI's CEO and rivals like Elon Musk recently backed calls to slow down AI development until safety catches up.